Maximized Hemostasis

• References

• 1 Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase. N J Clin Chem Clin Biochem 1989; 27: 277-85.
• 2 Campbell W, Okada H. An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989; 162: 933-9.
• 3 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
• 4 Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
• 5 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
• 6 Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascade through the thrombinthrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
• 7 Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 334: 5611-6.
• 8 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
• 9 Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombindependent activation of plasma carboxypeptidase B. Thromb Haemost 1998; 79: 371-7.
• 10 von dem Borne PAK, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a TAFI-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
• 11 Lisman T, Mosnier LO, Lambert T. et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
• 12 Mosnier LO, Lisman T, van den Berg HM. et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increaseing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-9.
• 13 Walsh PN, Rizza CR, Matthews JM. et al. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol 1971; 20: 463-75.
• 14 Francis CW, Markham Jr RE, Barlow GH. et al. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
• 15 Weitz JI, Hudoba D, Massel J, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin-independent inhibitors. J Clin Invest 1990; 86: 385-91.
• 16 Reganon E, Ferrando F, Vila V. et al. Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone. Haemostasis 1998; 28: 99-105.
• 17 Nagashima M, Werner M, Wang M. et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-42.
• 18 Chen L, Nichols W, Mattsson C. et al. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissueplasminogen activator improves thrombolysis. J Pharmacol Exp Ther 1996; 277: 1276-83.
• 19 Mattsson C, Bjorkman JA, Abrahamsson T. et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran). Thromb Haemost 2002; 87: 557-62.
• 20 Varadi K, Siekmann J, Turecek PL, Schwarz HP, Marder VJ. Phospholipidbound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation. Thromb Haemost 1999; 82: 1673-9.